Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial
Key Findings
Dornase alfa, when administered through nebulization, effectively reduced systemic inflammation in severe COVID-19 pneumonia patients, as shown by a 33% reduction in C-reactive protein (CRP) levels compared to standard care.
Practical Solutions
The use of dornase alfa led to a 63% increase in live discharge rates, higher lymphocyte counts, and reduced levels of circulating cf-DNA and D-dimer, indicating a potential improvement in patient outcomes.
Value
The trial demonstrates the benefit of cost-effective therapies targeting extracellular chromatin, providing a practical solution for reducing pathogenic inflammation in COVID-19 pneumonia.
Funding and Clinical Trial Number
Funding for the trial was provided by LifeArc, Breathing Matters, and The Francis Crick Institute. The clinical trial was registered under NCT04359654.
PMID:39009040 | DOI:10.7554/eLife.87030
Clinical Trials and Medical Practice
Clinical trials play a crucial role in developing safe and effective treatments. It’s essential to translate their benefits into everyday medical practice. DocSym, an AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
Streamlining Healthcare Operations
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
By using AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routine. Learn more about how we can help at aidevmd.com.
